Renal cancer biomarkers of angiogenesis in renal cell carcinoma (RCC): a multicentre, prospective, non-randomised, observational study

Overview

No summary available.

Registry

who.int

Start Date

February 7, 2011

End Date

January 31, 2012

Last Updated

4 years ago

Study Type

Observational

Sex

All

Sponsor

•1\. Newly diagnosed histologically or cytologically confirmed renal cell carcinoma with a clear cell component; patients who have a radiological diagnosis of probable renal cell carcinoma can be included whilst still awaiting biopsy or surgery and once confirmed to have clear cell renal cell carcinoma, they will be included in the study. If their histology confirms a non\-clear cell renal cell carcinoma, they will be replaced.
•2\. Metastatic renal cell carcinoma with a clear cell component with previous nephrectomy but with no previous history of use of systemic therapy with the exception of immunotherapy, provera and bisphosphonates. Prior palliative radiotherapy is permitted.
•3\. Ability and willingness to provide written informed consent
•4\. Ability and willingness to co\-operate with study procedures, including blood and urine sampling
•5\. Aged greater than or equal to 18 years, either sex

•1\. Previous history of cancer other than RCC, autoimmune diseases or known active infection
•2\. Previous history of use of systemic therapy for treatment of renal cell carcinoma other than immunotherapy, provera and bisphosphonates. Prior palliative radiotherapy is not an exclusion criterion.
•3\. Patients who commence therapy in between study visits (sample collection); although if the first sample is already collected before starting treatment, then that sample will be processed and the second sample will not be collected
•4\. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)\-related illness, HBV and HCV